EPICENTRX, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.epicentrx.com
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT05966194
- Locations
- 🇺🇸
Willis Knighton Cancer Center, Shreveport, Louisiana, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 292
- Registration Number
- NCT05566041
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04673942
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸California Cancer Associates for Research and Excellence, cCARE, San Marcos, California, United States
🇺🇸Providence Saint John's Health Center, Santa Monica, California, United States
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04525014
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03699956
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Millennium Oncology, Houston, Texas, United States
Expanded Access for PSV Personalized Oncolytic Viruses
- Conditions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- EpicentRx, Inc.
- Registration Number
- NCT03529539
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03515538
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02871843
- Locations
- 🇺🇸
The Cancer Institute of New Jersey (Rutgers University), New Brunswick, New Jersey, United States
🇺🇸University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Weill Cornell Brain Tumor Center, New York, New York, United States
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
- Conditions
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02801097
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of California, Davis, Sacramento, California, United States
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02518958
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States